MarketPulse

Rule 10b5-1 plan

9 articles
The Motley FoolThe Motley Fool··Seena Hassouna

Pharvaris Director's Stock Sale Pales Against Upcoming Clinical Catalysts

Pharvaris director's modest 1.80% stock sale matters less than upcoming Phase 3 data and FDA submission catalysts arriving in 2026.
PHVSclinical-stage biotechPhase 3 trial
The Motley FoolThe Motley Fool··Cory Renauer

Dianthus CFO Sells $739K in Stock as Biotech Eyes Phase 3 Success

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.
DNTHmonoclonal antibodybiotech
The Motley FoolThe Motley Fool··Robert Izquierdo

Beam Therapeutics CEO Sells $739K in Stock, But Strong Financials Suggest Confidence Remains

Beam Therapeutics CEO John Evans sold 30,078 shares for $739K via pre-planned tax obligation. Strong 2025 revenue growth and $1.2B cash reserves indicate company health.
BEAMbiotechinsider sale
The Motley FoolThe Motley Fool··Pamela Kock

Dianthus CFO Cashes Out $9.5M in Stock After 402% Rally

Dianthus CFO Ryan Savitz sold $9.5M in stock, liquidating all direct holdings while retaining options, following the company's exceptional 402% year-over-year rally.
DNTHmonoclonal antibodybiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Apogee CEO Sells $1.5M in Stock Despite 100% Surge; Clinical Data Tells Real Story

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.
APGEbiotechclinical trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Palvella Stock Soars 340% as COO Executes Pre-Planned Share Sale

Palvella COO sells ~$508K in shares via pre-planned trading arrangement amid 340% annual surge, driven by strong Phase 3 QTORIN rapamycin data and upcoming NDA submission.
PVLAbiotechclinical-stage
The Motley FoolThe Motley Fool··Jonathan Ponciano

Delek Director Trims $338K Position as Stock Soars 180% in Year

Delek US Holdings director sells $338K of stock via pre-arranged plan after 180% annual surge, signaling profit-taking rather than bearish outlook on refining operations.
DKenergy companystock surge
The Motley FoolThe Motley Fool··Andy Gould

Visteon CEO Divests $4.6M in Shares Through Planned Options Exercise

Visteon CEO Sachin Lawande sold 49,453 shares worth $4.62M via pre-scheduled trading plan, reducing holdings by 13% while maintaining over 321,000 shares.
VCexecutive compensationportfolio management
The Motley FoolThe Motley Fool··Adé Hennis

Century Aluminum CEO Cashes In $8.3M as Aluminum Prices Hit 4-Year Peak

Century Aluminum CEO sells $8.3M in shares as aluminum prices hit 4-year highs, leveraging pre-arranged trading plan amid geopolitical supply disruptions.
CENXgeopolitical tensionsinsider selling